8. Eficacia y seguridad comparativa de los medicamentos de segunda línea para el estatus epiléptico: Un metanálisis en red

Francisco Javier Brincau García

Francisco Javier Brincau García Servicio de Pediatría y Áreas Específicas. Hospital General Universitario Gregorio Marañón. Madrid

Palabras clave: Estatus epiléptico, Tratamiento segunda linea

Abstract

Se presenta un comentario sobre un metaanálisis que evalúa la eficacia y seguridad de los tratamientos de segunda línea para el estatus epiléptico en niños y adultos. Se analiza la metodología utilizada en el estudio, los resultados obtenidos y se discuten posibles sesgos que podrían haber influido en las conclusiones.

This commentary reviews a meta-analysis on the efficacy and safety of second-line treatments for status epilepticus in both children and adults. It examines the study's methodology, the results, and discusses potential biases that may have impacted the conclusions.

Citas

Sánchez Fernández I, Gaínza-Lein M, Lamb N, Loddenkemper T. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Neurology. 2019;92(20): 2339-2348. doi: 10.1212/WNL.0000000000007503. PMID: 31068480.

Brigo F, Del Giovane C, Nardone R, Trinka E, Lattanzi S. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: A systematic review and network meta-analysis. Epilepsy Behav. 2019;101(Pt B):106466. doi: 10.1016/j.yebeh.2019.106466. Epub 2019 Aug 25. PMID: 31462385.

Kunst S, Rojo M, Schmidbauer ML et al. IGNITE Study Group. Phenobarbital in super-refractory status epilepticus (PIRATE): A retrospective, multicenter analysis. Epilepsia. 2023;64(6):1482-1492. doi: 10.1111/epi.17608. Epub 2023 Apr 16. PMID: 37021609.

Jain P, Aneja S, Cunningham J, Arya R, Sharma S. Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses. Seizure. 2022;102:74-82. doi: 10.1016/j.seizure.2022.09.017. Epub 2022 Sep 26. PMID: 36209676.

Chamberlain JM, Kapur J, Shinnar S et al. Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217-1224. doi: 10.1016/S0140-6736(20)30611-5. Epub 2020 Mar 20.

Yi ZM, Zhong XL, Wang ML, Zhang Y, Zhai SD. Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:751. doi: 10.3389/fphar.2020.00751. PMID: 32670054; PMCID: PMC7326124.

McTague A, Kneen R, Kumar R, Spinty S, Appleton R. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. Seizure. 2012;21(7):529-34. doi: 10.1016/j.seizure.2012.05.010. Epub 2012 Jun 19. PMID: 22722010.

Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R; NETT and PECARN Investigators. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019;381(22):2103-2113. doi: 10.1056/NEJMoa1905795. PMID: 31774955; PMCID: PMC7098487.